General practitioner and nurse experiences of type 2 diabetes management and prescribing in primary care: a qualitative review following the introduction of funded SGLT2i/GLP1RA medications in Aotearoa New Zealand.


Journal

Primary health care research & development
ISSN: 1477-1128
Titre abrégé: Prim Health Care Res Dev
Pays: England
ID NLM: 100897390

Informations de publication

Date de publication:
16 Sep 2024
Historique:
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: epublish

Résumé

To explore the views of general practitioners (GPs) and nurses on type 2 diabetes (T2D) management, including the use of recently funded T2D medications in New Zealand (NZ) and their perceived barriers to providing optimal care. T2D is a significant health concern in NZ, particularly among Māori and Pacific adults. Characterised by prolonged hyperglycaemia, T2D is generally a progressive condition requiring long-term care. Semi-structured interviews were conducted between July and December 2022 with 21 primary care clinicians (10 GPs and 11 nurses/nurse prescribers) from nine different general practice clinics across the Auckland and Waikato regions of NZ. Framework analysis was conducted to identify common themes in clinicians' perceptions and experiences with T2D management. Three themes were identified: health-system factors, new medications, and solution-based approaches. Lack of clinician time, healthcare funding, staff shortages, and burn-out were identified as barriers to T2D management under health-system factors. The two newly funded medications, empagliflozin and dulaglutide, were deemed to be a positive change for T2D care in that they improved patient satisfaction and clinical outcomes, but several clinicians were hesitant to prescribe these medications. Participants suggested that additional education and specialist diabetes support would be helpful to inform optimal medication prescribing and that better use of a multi-disciplinary team (clinical and support staff) could support T2D care by reducing workload, addressing cultural gaps in healthcare delivery, and reducing burnout. An improved primary care work environment, including appropriate professional development to support prescribing of new medications and the value of collaboration with a non-regulated workforce, may be required to facilitate optimal T2D management in primary care. Future research should focus on interventions to increase support for both clinical teams and patients while adopting a culturally appropriate approach to increase patient satisfaction and improve health outcomes.

Sections du résumé

AIM OBJECTIVE
To explore the views of general practitioners (GPs) and nurses on type 2 diabetes (T2D) management, including the use of recently funded T2D medications in New Zealand (NZ) and their perceived barriers to providing optimal care.
BACKGROUND BACKGROUND
T2D is a significant health concern in NZ, particularly among Māori and Pacific adults. Characterised by prolonged hyperglycaemia, T2D is generally a progressive condition requiring long-term care.
METHODS METHODS
Semi-structured interviews were conducted between July and December 2022 with 21 primary care clinicians (10 GPs and 11 nurses/nurse prescribers) from nine different general practice clinics across the Auckland and Waikato regions of NZ. Framework analysis was conducted to identify common themes in clinicians' perceptions and experiences with T2D management.
FINDINGS RESULTS
Three themes were identified: health-system factors, new medications, and solution-based approaches. Lack of clinician time, healthcare funding, staff shortages, and burn-out were identified as barriers to T2D management under health-system factors. The two newly funded medications, empagliflozin and dulaglutide, were deemed to be a positive change for T2D care in that they improved patient satisfaction and clinical outcomes, but several clinicians were hesitant to prescribe these medications. Participants suggested that additional education and specialist diabetes support would be helpful to inform optimal medication prescribing and that better use of a multi-disciplinary team (clinical and support staff) could support T2D care by reducing workload, addressing cultural gaps in healthcare delivery, and reducing burnout. An improved primary care work environment, including appropriate professional development to support prescribing of new medications and the value of collaboration with a non-regulated workforce, may be required to facilitate optimal T2D management in primary care. Future research should focus on interventions to increase support for both clinical teams and patients while adopting a culturally appropriate approach to increase patient satisfaction and improve health outcomes.

Identifiants

pubmed: 39282819
pii: S1463423624000264
doi: 10.1017/S1463423624000264
doi:

Substances chimiques

Sodium-Glucose Transporter 2 Inhibitors 0
Hypoglycemic Agents 0
Glucagon-Like Peptide-1 Receptor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e34

Auteurs

Kimberley Norman (K)

School of Primary and Allied Health Care, Monash University, Melbourne, Australia.

Sara Tareq Mustafa (ST)

Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.

Shemana Cassim (S)

School of Psychology, Massey University, Auckland, New Zealand.

Hilde Mullins (H)

Department of Nursing, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.

Penny Clark (P)

Northcare Medical Centre, Hamilton, New Zealand.

Rawiri Keenan (R)

Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.

Leanne Te Karu (L)

Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Rinki Murphy (R)

Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Ryan Paul (R)

Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.
Te Whatu Ora Health New Zealand, Hamilton, New Zealand.

Tim Kenealy (T)

Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Lynne Chepulis (L)

Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH